SPECIALIZED EDUCATIONAL SERIES DESIGNED TO EMPOWER HEALTHCARE PROFESSIONALS (JUST LIKE YOU!) WITH THE LATEST ADVANCEMENTS IN DIABETES TECHNOLOGY
Real Patient Case Studies with Implantable CGM
In this case-based presentation, endocrinologists Dr. Steve Edelman, Dr. Jeremy Pettus, and Dr. David Ahn share real-world evidence of how Eversense 365 CGM adapts to diverse patient lifestyles. Through three distinct cases—a snorkeling instructor with Type 2 diabetes, a rock climber with needle phobia, and a competitive cyclist—they demonstrate practical solutions for challenging clinical scenarios. The presentation walks through key metrics, therapeutic adjustments, and specific features like underwater vibratory alerts and avoiding compression lows that impact patient outcomes. Whether you’re looking to expand your CGM choices or solve specific patient challenges, these cases will show you how implantable CGM technology can address common barriers to adherence while supporting patients with unique lifestyle needs.
WATCH OTHER VIDEOS FROM THIS SERIES
About the Eversense 365-day Implantable CGM Sensor
In this new video, Dr. Steve Edelman and Dr. Jeremy Pettus explore the newly FDA-approved Eversense 365-day implantable CGM sensor—a unique addition to diabetes management options. Through this series, you’ll gain valuable insights into the benefits and distinctions between transcutaneous and implantable CGMs, equipping you with the knowledge to guide patients in choosing the best solution for their lifestyle and clinical needs.
Discover how extended wear time, discreet vibratory alerts, and the flexible, removable transmitter make the Eversense sensor a compelling choice for patients with active lifestyles, specific workplace requirements, or those seeking alternative CGM options.
Watch Full Insertion Procedure
In this comprehensive procedural demonstration, endocrinologist Dr. David Ahn performs the Eversense 365 CGM insertion on Dr. Steve Edelman, while Dr. Jeremy Pettus provides expert insights—both endocrinologists have been living with Type 1 diabetes since age 15. The video breaks down each step of the 10 min insertion technique, showing the clinical practicality of this in-office procedure that provides patients with a full year of continuous glucose monitoring. For healthcare providers considering Eversense 365 CGM, this guide clarifies both the insertion process and the option to refer patients to certified inserters, highlighting how this once-yearly procedure eliminates frequent sensor changes and reduces common CGM pain points in clinical practice.
LEARN ALL ABOUT THE EVERSENSE IMPLANTABLE CGM
Understanding Eversense Implantable CGM:
- Extended Wear Period: Up to 365 days of use
- On-Body Vibratory Alerts: Alternative notification method
- Unique Form Factor: Implantable sensor with removable transmitter
- Prescription Efficiency: Fewer sensor changes mean reduced prescription hassles for patients and healthcare providers like you
- Calibration Requirements: Periodic calibration needed for the accuracy of the sensor
- Reduced Skin Irritation: Gentle silicon adhesive
- Alternative for Active Lifestyles: Option for water sports enthusiasts
What type of patients might consider the Eversense Implantable Sensor?
- Patients with type 1 or type 2 diabetes on insulin therapy
- Those with active lifestyles or specific workplace requirements
- Individuals seeking alternative options between other available CGM systems
- Reduced Skin Irritation: Gentle silicon adhesive
- Alternative for Active Lifestyles: Option for water sports enthusiasts
MEET YOUR EXPERT SPEAKERS
Here at TCOYD®, we create educational diabetes content to support both healthcare professionals and individuals living with diabetes. Taking a proactive role in learning about the latest diabetes technology is vital to choosing the right tools to help you stay at the forefront of patient care. Dr. Steve Edelman and Dr. Jeremy Pettus, who have lived with diabetes for 54 years, have experienced it all. They are sharing their thoughts with Dr. David Ahn, an experienced endocrinologist who always stays on top of diabetes technology knowledge.
STEVEN V. EDELMAN, MD
Founder & Director, TCOYD®; Endocrinologist; Professor of Medicine, UCSD School of Medicine, VA Medical Center, San Diego, California; Board Member, Senseonics
JEREMY PETTUS, MD
Type 1 Track & Professional Education Director, TCOYD®; Endocrinologist; Associate Professor of Medicine, UCSD School of Medicine, San Diego, CA
DAVID AHN, MD
Endocrinologist; Chief of Diabetes Services, Hoag Medical Group, Newport Beach, California
– TCOYD® Faculty Disclosures –
Dr. Edelman is on the Board of Directors at Senseonics